GFC Life Science said on the 6th that it has fully entered the filler business, beginning domestic sales of its hyaluronic acid (HA)-based GFCCELL Luxe Filler.
The HA-based medical device GFCCELL Luxe Filler was developed with a focus on procedural safety and delivering natural-looking volume. With a lineup featuring various viscosities, it is designed to meet complex treatment needs such as facial contouring, volume enhancement, and skin improvement.
The product is a key new flagship under GFC Life Science's in-house brand in the medical aesthetics field, and the company plans to use it to expand its product portfolio and build a foundation for mid- to long-term growth.
GFC Life Science signed a memorandum of understanding (MOU) with Person Healthcare, a global marketing company for hospital and clinic pharmaceuticals and medical devices, and began domestic distribution. At the same time, it is pushing overseas exports of filler products by leveraging the distribution network in 32 countries built through its existing skin booster business.
The company has designated Türkiye, Indonesia, and Saudi Arabia—markets with high filler demand—as priority entry countries and is proceeding with country-specific medical device certification and registration. It is also conducting pre-sales activities centered on these countries. The company said these regions are seeing strong growth in the filler market, supported by a growing preference for nonsurgical aesthetic procedures, the expansion of medical tourism, and a rising middle class.
It is also preparing to enter the European market. GFC Life Science aims to complete certification under the existing Medical Device Directive (MDD) by June this year, while setting certification under the strengthened Medical Device Regulation (MDR) as a mid- to long-term task, with plans to complete the transition by 2027.
Kang Hee-cheol, CEO of GFC Life Science, said, "The medical aesthetics business is a core area that will drive the company's mid- to long-term growth," adding, "Along with securing a foothold in the domestic market, we will gradually increase our market share in key countries such as Türkiye and Saudi Arabia." Kang added, "We will also proceed with the European certification process without delay to strengthen our position in the global market."
Kang Hee-cheol, CEO of GFC Life Science, said, "The medical aesthetics business is a key engine that will drive our mid- to long-term growth," adding, "We will quickly secure market share in key hub countries such as Türkiye and Saudi Arabia while establishing ourselves in the domestic market." Kang added, "We will also complete the step-by-step certification process in Europe without delay to solidify our position in the global aesthetics market."